Skip to content

NHP iPSC-Cardiomyocytes for Translational Cardiac Screening

A Translational in-vitro screening platform using Non-Human PrimateiPSC-derived ventricular cardiomyocytes
Download now
Screenshot 2026-05-13 at 4.14.16 PM

This poster presents Ncardia’s non-human primate (NHP) iPSC-derived ventricular cardiomyocyte platform, developed for scalable, high-throughput functional screening and translational cardiac safety assessment. 

Download it now for a closer look at:

  • How NHP iPSC-derived cardiomyocytes can be manufactured at scale while maintaining high purity, structural fidelity, and stable functional performance
  • Comparative MEA and impedance assay data highlighting species-specific electrophysiological and contractile responses between human and NHP cardiomyocytes
  • How acute and chronic drug exposure studies reveal differences in arrhythmia sensitivity, cytotoxicity, and contractility profiles across species
  • Functional characterization data demonstrating robust responses to cardioactive compounds including nifedipine, dofetilide, quinidine, and sunitinib
  • How this platform supports cross-species interpretation of screening and safety data in advanced discovery workflows

Download the Poster



Get the Poster Now!

Whether you are developing translational safety assays or evaluating cardiac liabilities during drug discovery, this platform provides a scalable, reproducible system for long-term functional screening using NHP cardiomyocytes.

Download the poster by filling out the form below: